PEGylation of interferon alpha 2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

Lisa M Kaminskas; David B Ascher; Victoria M McLeod; Marco J Herold; Caroline P Le; Erica K Sloan; Christopher JH Porter

Journal article

PEGylation of interferon alpha 2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

Lisa M Kaminskas, David B Ascher, Victoria M McLeod, Marco J Herold, Caroline P Le, Erica K Sloan, Christopher JH Porter

Journal of Controlled Release | ELSEVIER | Published : 2013

DOI: 10.1016/j.jconrel.2013.03.006

University of Melbourne Researchers

Marco Herold Author Medical Biology (W.E.H.I.)

David Ascher Author Biochemistry and Pharmacology

Grants

Awarded by NHMRC

Awarded by NIH

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

The authors would like to acknowledge funding support by the Samuel Nissen Charitable Foundation (managed by Perpetual Trustees, Australia). LMK was supported by an NHMRC Career Development fellowship. EKS is supported by a National Breast Cancer Foundation fellowship, NIH CA160890 and NHMRC 1008865. This work was supported in part by infrastructure funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent's Institute.